Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant
Diabetes Care. ISSN 0149-5992.
Berk-Planken, I.I.L. (Ingrid); Hoogerbrugge, N. (Nicoline); Stolk, R.P. (Ronald); Bootsma, A.H. (Aart); Jansen, H. (Hans)
OBJECTIVE: Hepatic lipase (HL) is involved in the metabolism of several
lipoproteins and may contribute to the atherogenic lipid profile in type 2
diabetes. Little is known about the effect of cholesterol synthesis
inhibitors on HL activity in relation to sex and the hepatic lipase gene,
the LIPC promoter variant in type 2 diabetes. Therefore, we studied the
effect of atorvastatin 10 mg (A10) and 80 mg (A80) on HL activity in 198
patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients (aged
45-75 years, without manifest coronary artery disease, total cholesterol
4.0-8.0 mmol/l, and fasting triglycerides [TG] 1.5-6.0 mmol/l) were
included in a double-blind, randomized, placebo-controlled trial for 30
weeks (Diabetes Atorvastatin Lipid Intervention study). RESULTS: HL
activity at baseline was significantly higher in our population compared
with an age-matched control group without type 2 diabetes (406 +/- 150 vs.
357 +/- 118 units/l). HL activity in men versus women (443 +/- 158 vs. 358
+/- 127 units/l), in carriers of the LIPC C/C allele versus carriers of
the T/T allele (444 +/- 142 vs. 227 +/- 96 units/l), and in Caucasians
versus blacks (415 +/- 150 vs. 260 +/- 127 units/l) all differed
significantly (P < 0.001). Atorvastatin dose-dependently decreased HL
(A10, -11%; A80, -22%; both P < 0.001). Neither sex nor the LIPC C-->T
variation influenced the effect of atorvastatin on HL activity.
CONCLUSIONS: Sex, LIPC promoter variant, and ethnicity significantly
contribute to the baseline variance in HL activity. Atorvastatin treatment
in diabetic dyslipidemia results in a significant dose-dependent decrease
in HL activity, regardless of sex or the LIPC promoter variant.